Antimicrobial Resistance by Radic, Jan et al.
  
http://universityobserver.netsoc.com/wp-content/uploads/2012/02/jhgvhgfc.jpg 
 
  
1st Semester Project 
Kristian Sørensen 
Ernesto Calderon 
Marta Stenz 
Jan Radic 
Sibghat Ullah 
 
Supervisor: Biljana Mojsoska 
13.2 International Natural Science Roskilde University 
Antimicrobial Resistance 
Fall Semester [ANTIMICROBIAL RESISTANCE] 
 
1st Semester project Page 1 
 
Abstract 
 
Antimicrobial resistance has been increasing alongside with antibiotic use, and with less new 
antibiotics being produced it is imperative to find new ways to treat bacterial infections. The causes 
of resistance are numerous. 
Although it is not completely clear how the resistant genes are created, it is known that the selective 
pressure created due to anthropogenic activities has led to the creation of environmental reservoirs 
of antibiotic resistance, and that the overuse and misuse in both animals and humans is a key factor 
in the acquisition of resistance genes. 
The discovery of multidrug resistance strains in both communities and hospitals is a wakeup call to 
take on this problem that raises the morbidity and mortality rates for strains that were sensible to 
specific antibiotics in the past, such as Staphylococcus aureus to penicillin. There is a need for 
creation of new drugs and new therapeutic approaches. 
In this investigation, MIC testing was done to test the efficiency of two conventional antibiotics; 
Ampicillin and Tetracycline, and one antimicrobial peptide; Polymyxin B. The purpose of this was 
to find out whether or not antimicrobial peptides are an efficient and effective alternative to 
conventional antibiotics. 
Through these experiments, it was concluded that Polymyxin B was a great alternative to both 
Ampicillin and Tetracycline in the treatment of Escherichia coli. 
3,9µg/ml of Polymyxin B was needed in the experiment to inhibit bacterial growth, compared to 
62,5µg/ml of Tetracycline. 
However, due to its natural properties, Polymyxin B was not effective against Staphylococcus 
aureus. In response to the results observed when tested on E. coli, it can be concluded that 
antimicrobial peptides can and should be used as an alternative to conventional antibiotics, for the 
treatment of bacteria, such as E. coli. 
This can potentially help solve the problem of antibiotic resistant strains of bacteria. With more 
antimicrobial drugs on the market, physicians will have more options when treating patients for 
bacterial infections, and mortality due to infection will decrease as a result. 
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Problem area  
 
Alexander Fleming discovered Penicillin in 1928, but it was not before 1943 that it was purified 
and mass produced by Andrew J. Moyer, in a process called industrial fermentation. Three years 
later, the first bacteria resistant to penicillin had been isolated (Daily Science 22. october 2012). 
Since then there has been an increased concern about antibiotic resistance. 
 
There can be three reasons for antibiotic resistance; natural selection, misuse in livestock and 
overuse of antibiotics by the population. 
 
Bacteria are living organisms that can adapt to almost any environment they are exposed to, by the 
mutations that are created. If the new mutations contribute to any significant increase in 
survivability, they become dominant and their genome is passed on to other bacteria. 
 
The most important cause for antibiotic resistance is due to the overuse of antibiotics, especially by 
general practitioners. The doctors may do insufficient diagnosis and prescribe unnecessary broad 
spectrum antibiotics – or the patients may finish their antibiotic treatment before time.  
 
In the 1940s, the growth-promoting effects of antibiotics were first discovered. Poultry farmers 
began treating their chickens with byproducts of Tetracycline fermentation, with the result that the 
treated chicken grew more rapidly, than those that were not treated. Since then, it has become 
common practice to use antibiotics as growth-promoters, and to give antibiotics to healthy 
livestock, in order to minimize diseases. While this has maximized the profits for farmers, we are 
now realizing what the consequences are for our society. 
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Problem formulation 
 
The antimicrobial resistance issues need to be addressed in two ways; there has to be political 
solutions on how to reduce the over usage of antibiotics – and we also need to develop new 
antimicrobial agents, so that we can fight bacteria that are almost resistant to all antibiotics. 
One type of bacteria that has begun causing monumental problems due to resistance is methicillin-
resistant Staphylococcus aureus, more commonly known as MRSA. MRSA cannot be cured with 
the antibiotic treatments that will typically cure a staph infection (Definition 2010). While this 
bacterium is commonly found on the surface of the skin, it can be extremely harmful when it enters 
the body. Here it can cause infections in the blood, the bones, the joints, and in the organs 
(Definition 2010). Since it is often impossible to kill with antibiotics due to resistance, MRSA can 
be fatal. People who have weakened immune systems are particularly susceptible. For this reason, 
MRSA infections often spread among hospitalized persons (Definition 2010). 
Because bacteria such as Staphylococcus aureus are developing multi-resistance to conventional 
antibiotics, it is crucial that alternatives to these drugs are researched and developed. New 
approaches, such as the use of antimicrobial peptides, a naturally occurring compound found in all 
classes of life, could be employed to fight bacteria that are resistant to antibiotics. As each new 
antibiotic drug is only a temporary solution, new methods such as this, must be developed.  
The issue of antibiotic resistance is one of grave urgency and importance. Bacteria such as E. coli 
or Staphylococcus can be harmful to humans, and even fatal if untreatable. If bacteria cannot be 
killed, there will be a dramatic increase in mortality rates due to bacterial infections. The morbidity 
will also greatly increase, thus creating more hospitalizations. Therefore changes must be made to 
slow antibiotic resistance, and develop alternatives for treating infections. 
 
It is hypothesized that antimicrobial peptides will kill harmful bacteria just as effectively as 
conventional antibiotics. 
The problem and question that must be solved now is whether antimicrobial peptides provide 
an efficient and effective alternative to conventional antibiotics. 
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Aim of the project 
 
The aim of this project is to determine whether antimicrobial peptides are an acceptable alternative 
to conventional antibiotics. This constitutes that the peptides are as efficient and effective as 
conventional antibiotics are at curing bacterial infections. In addition, a main goal of this 
experiment is to discover how the development of antibiotic resistance in bacteria populations 
differs from conventional treatments to peptide treatments. From this investigation, an 
understanding will be gained about how bacteria develop resistance, and also of the magnitude of 
the problem that this causes for society. 
The research done will also clarify how antibiotics and antimicrobial peptides function, and how 
the mechanisms of both differ from one another. 
Finally, we will be doing experiments with Escherichia coli and Staphylococcus aureus. The 
bacteria will be paired with Tetracycline, Ampicillin and Polymyxin B, and then the minimum 
inhibitory concentration will be measured. This will give us the opportunity to compare the 
efficiency of conventional antibiotics versus antimicrobial peptides. 
The semester theme involves using scientific knowledge as a tool to solve current problems in 
technology and in society. The framework of this project is in accordance with the goals laid out in 
the semester theme. The issue of antibiotic-resistant bacteria is causing grave concern in our 
society. While this problem can be analyzed and approached from many angles, such as from a 
social or political perspective, this project will focus on empirical data, and on describing already 
published research. In this investigation, the goal is to use science to ameliorate the problem of 
bacteria resistance through researching and testing alternatives, specifically antimicrobial peptides.  
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Target group and motivation 
 
In a world where pathogenic bacteria are developing resistance at more rapid rates than ever before, 
and where there is very little incentive for pharmaceutical companies to invest in the development 
of new antibiotics, it is crucial that this issue becomes a focus. 
 
In the agricultural industry, farmers are overusing antibiotics so that they can compromise on health 
and living conditions of livestock, and to benefit from the growth promoting effects of the 
antibiotics. In the medical field, medical professionals are cutting corners in making accurate 
diagnoses and are prescribing antibiotics to patients who may be suffering from minor illnesses or 
even viral infections, which cannot be treated with antibiotics. Furthermore, patients who are 
misinformed may discontinue use of prescribed antibiotics as soon as they notice an improvement 
in their symptoms. This incomplete dosage actually promotes the development of antibiotic 
resistant strains of bacteria. For all of these reasons, it is crucial that the public, as well as medical 
professionals are made aware of the growing dilemma that is bacteria resistance. Also, in order to 
fight bacterial infections, alternatives to conventional antibiotics must be researched and developed. 
 
Therefore, it is important that students within the field of natural science are made aware of this 
problem, as it is these individuals that represent the future of medicine, and of scientific research. 
For this reason, the following write-up is targeted at the general public in hopes of informing the 
misinformed, and at the future generation of medical professionals, in hope that this will generate 
awareness of the gravity of the issue at hand, and of the need for new alternatives. 
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Introduction 
 
Cells are the most basic unit of life, and can be categorized in two different kinds: prokaryotes and 
eukaryotes. Bacteria and Archaea belong to prokaryotes, and it is assumed that bacteria were the 
first form of life that existed on our planet. This is among many things, based on the research that is 
done on fossil stromatolites, which are about 3,5 billion years old, and are built of numerous layers 
of Cyanobacteria. Fossil stromatolites are found at shallow coastal waters, and are almost identical 
to the stromatolites that are growing in the ocean today. Approximately 1500 million years later, 
the eukaryotes evolved which include all multicellular organisms. 
Bacteria and their characteristics 
 
Prokaryotes are much smaller and simpler organisms than eukaryotes. 
But both types of cells share some basic features; the plasma membrane functions as a selective 
barrier, which makes sure that oxygen, nutrients and waste is being filtered in and out of the cell. 
The cytoplasm is a colorless fluid where subcellular components are found. In prokaryotic cells, all 
the content is inside the cytoplasm. Instead the eukaryotic cells have organelles inside the 
cytoplasm, which are protected by a double membrane. The biggest organelle in the eukaryotic cell 
is most often the nucleus, where the chromosomes containing the DNA are located. This is one of 
the biggest differences between eukaryotes and prokaryotes, since their DNA is found in the 
nucleoid instead, which does not have a membrane. Another important difference is the flagellum, 
which is responsible for the movement of cells.  
While eukaryotic cells have a far more advanced flagellum that can move back and forth, the 
prokaryotic one is a bit simpler and just turns around like a screw (Campbell, 2002). 
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Bacterial cell division 
 
The way prokaryotes reproduce, is by an asexual method called binary fission. 
Most of the genetic material in bacteria is found in a single chromosome, which consists of a 
circular DNA molecule. When this DNA starts to replicate at a specific point on the chromosome, it 
begins the cell division (Figure 1). This is also known as the origin of replication – creating two 
origins out of one. While the chromosome is replicating, one of the origins move to the opposite 
side. Now the cell grows to approximately twice its original size, and shortly after the plasma 
membrane moves inward and divides the cell. 
 
 
Figure 1: Cell division (Campbell, 2002). 
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Gram-positive and Gram-negative bacteria 
 
Bacteria are sorted into two different classes; Gram-negative and Gram-positive (Figure 2). 
The origin of this nomenclature comes from the Hans Christian Gram (HCG) staining test. Gram-
negative bacteria did not hold the dye during the staining processes while Gram-positive bacteria 
did. The reason for the differences in the staining is because of the bacteria’s cell wall structure 
(Hussey, Smith, 2005). 
The sequence of staining begins with crystal violet where all cells take up the dye, and then it is 
stained with iodine, which lightens the violet color. Afterwards the cells are decolorized with 
alcohol where only Gram-positive bacteria hold the purple dye, and finally the cells are dyed with 
safranin which gives the Gram-negative bacteria the pink color. 
 
Figure 2: Gram-negative and Gram-positive structure (Todar, 2009).  
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Gram-negative bacteria have an outer membrane layer, which is made of phospholipids, proteins, 
porins and lipopolysaccharides. In addition, the outer membrane also contains lipoproteins, which 
run down and connect to the peptidoglycan layer. 
Next, is the peptidoglycan layer, and underneath is the periplasmic space, which is filled with 
enzymes. Finally, the last layer is the inner membrane layer, which also consists of phospholipids, 
fatty acids, and proteins.  
Unlike Gram-negative bacteria, Gram-positive bacteria are not as complex structurally or 
chemically. Gram-positive bacteria have a much thicker peptidoglycan layer; in addition, the layer 
has lipoteichoic and teichoic acids that run through the entire layer and connects to the inner 
phospholipid layer. Like Gram-negative bacteria, Gram-positive bacteria have a periplasmic space 
filled with enzymes followed by the inner phospholipid membrane.  
The phospholipids are phosphate heads that have fatty acid, lipids, tails that when lined up together 
create a bilayer membrane for both bacteria’s cell membranes. Referring to Figure 3.a one can see 
the chemical structure as well as the hydrophobic and hydrophilic ends, which will be very 
important to understand when learning how antimicrobial peptides kill bacteria. 
In Gram-negative bacteria the outer membrane consists of lipopolysaccharides (LPS), which help 
the structural integrity of the bacteria’s cell wall as well as being an endotoxin, which upon 
breakdown of the cell wall causes toxicity and inflammation. In addition, LPS also increase the 
negative charge the membrane gives off. Porins are pore like structures that allow specific 
molecules to pass through the membrane.  
In Gram-positive bacteria, teichoic and lipoteichoic acids exist to help with keeping the 
peptidoglycan sugar chains from breaking apart, act as an adhesive to host cells, and also increase 
the negative charge the membrane gives off.  Both bacteria have a peptidoglycan layer; Gram-
negative’s layer is around 7-8 nanometers while Gram-positive bacteria can be anywhere around 
20-80 nanometers. The purpose of this layer is to give the bacteria shape and act as an anchor for 
proteins; in the case of Gram-positive bacteria the layer stops any molecule bigger than 2 
nanometers from passing through the barrier. More importantly, the peptidoglycan layer counters 
osmotic pressure. 
Fall Semester [ANTIMICROBIAL RESISTANCE] 
 
1st Semester project Page 11 
 
Bacteria is usually hypertonic meaning it lets free water flow out of the membrane, and if it wasn’t 
for the peptidoglycan layer the osmotic pressure would force to much water inside the bacteria 
cytoplasm and it would burst or suffer from osmolysis. 
The cell wall is formed with sugars and amino acids. N-acetylmuramic acid (NAM) and N-
acetylglucosamine (NAG) are sugars that line up one after the other in rows. Five to seven amino 
acids are then connected to N-acetylmuramic and form a cross-link between rows from a mesh like 
3D structure (Todar, 2009). Figure 3.b shows the structure of E. coli peptidoglycan where four 
amino acids come off NAM, and the third amino acid (Meso-diaminopimelic acid; orange) 
connects to the last amino acid (D-alanine; light blue) of the other tetrapeptide link forming a 
interpeptide bond. The purpose of Figure 3 is to get a visual of the peptidoglycan structure; 
however, it is important to consider that the types of amino acids used vary. Furthermore, Gram-
positive peptidoglycan form their crosslinks with an interpeptide bridge made up of glycosidic 
molecules rather than the interpeptide bond in Gram-negative bacteria. It is the linkage of the 
peptides that give the peptidoglycan layer its strength to resist osmotic pressure. 
 
 
Figure 3. a): Phospholipid,  b): E. coli peptidoglycan structure (Todar, 2009). 
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Information on specific types of bacteria 
Escherichia coli 
 
A type of Gram-negative bacteria that causes serious threats to human health, and has caused 
problems due to antibiotic resistance, is Escherichia coli (Figure 4). The cell of the bacterium is 
rod-shaped, with adhesive fimbriae, which allow the bacterium to adhere to its host. Its cell wall is 
made up of an outer membrane, consisting of lipopolysaccharides, a peptidoglycan layer, and an 
inner cytoplasmic membrane (Jacques, 2011). Certain strains of E. coli can exchange plasmids with 
other bacteria. This provides an advantage to E. coli bacteria, allowing them to adapt and evolve 
quickly in stressful environments (Jacques, 2011).  
 
Figure 4: E. coli bacteria. 
http://firmitas.org/img/EColi.jpg 
 
E.coli is naturally present in the flora of the intestinal tract of humans. Infection occurs when there 
is a cross-contamination of food and the bacteria from feces. The lipopolysaccharides in the outer 
membrane of the cell wall function as endotoxins, which can lead to inflammation, hypotension, 
capillary damage, and shock when introduced to the blood stream. This can be fatal (CDC). Pilli on 
the outer membrane allow the bacteria cells to adhere to epithelial cells of mucous membranes 
within the body (Kaiser 2005). Certain strains secrete enterotoxins, which cause the loss of sodium 
ions and water from the intestines, causing diarrhea.  
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Other types of E.coli cause disease by producing a toxin called Shiga toxin. These categories of the 
bacteria are referred to as verocytoxic or enterohemorrhagic E.coli (CDC). These bacteria often 
cause symptoms such as stomach cramps, diarrhea, vomiting, and sometimes a mild fever. E.coli 
can also cause urinary tract infections, wound infections, septicemia, gastroenteritis, and neonatal 
meningitis (Kaiser 2005). In approximately 5-10 percent of the cases, the infected person will 
develop hemolytic uremic syndrome (HUS), a severe complication, which causes kidney 
malfunction. HUS requires hospitalization and is potentially life threatening (CDC). E. coli 
infections are typically treated with antibiotics such as Ampicillin, Cefoxitin, Doxycycline, or 
Rifaximin (Madappa). 
 
 
 
Figure 6: Percent resistance in E.coli blood isolates in humans, Denmark (DANMAP, 2011). 
Figure 5: Percent resistance of E. coli colonies in the United States (Center 2010). 
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As can be seen in Figure 5, 1,76% of E.coli bacteria in 2010 were resistant to multiple 
antimicrobial drugs. This is an increase in 0,31% in just one year. This is worrying, as it means an 
inevitable increase in the frequency of food bourne illness in the United States, which is difficult or 
impossible to treat. In Figure 6, it is shown that up to 50% of E.coli isolates are resistant to the 
antibiotic Ampicillin, one of the drugs that were tested in the experimental section of this report.  
E. coli bacteria are exhibiting multidrug resistance with increasing frequency. These strains are 
often resistant to up to six types of commonly used antibiotics (Manges, Johnson 2001). This has 
caused epidemics in several places in Europe. 
Multidrug resistant E. coli caused an outbreak of community-acquired cystitis, pyelonephritis, and 
septicemia in South London in 1987, and is a prevalent cause of urinary tract infection in 
Barcelona, Spain (Manges, Johnson 2001). From certain clinical and water samples taken in Zaria, 
Nigeria, E. coli strains showed high rates of resistance toward many antibiotics. 
For example, there was a resistance rate of 83.7% toward Ampicillin and a 66.8% resistance toward 
Tetracycline (Chigor et. al. 2010). Figure 7 shows the frequency of multidrug-resistance observed 
in these samples. 38.6% of the isolates tested were resistant toward the antibiotics Ampicillin, 
Tetracycline, Nalidixic acid, and Nitrofurantoin. 
The most multi-resistant strains were resistant to 9 different types of antibiotics. These extremely 
multi-resistant strains made up 1% of aquatic isolates tested. This is extremely worrying. If a 
person is infected with a strain of E. coli that is resistant to so many types of antibiotics, it is 
unlikely that treatment is possible. 
 
Figure 7: This chart shows the number and percentage of multidrug-resistant isolates obtained through aquatic and clinical 
samples in a study done in Zaria, Nigeria, as well as the types of antibiotics the isolates are resistant to (Chigor et. al. 2010). 
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Staphylococcus aureus 
 
A type of Gram-positive bacteria that are causing a threat due to antibiotic resistance is 
Staphylococcus aureus (Figure 8). These bacteria are spherical and exist naturally in irregular, 
grape-like clusters, in the nose and on the surface of the skin, and usually enter the body through 
the skin of the infected individual, by way of an accidental or postoperative wound (Kaiser 2005).  
These bacteria cause inflammation on the skin in the form of pus-filled lesions, or abscesses. The 
infection can also spread into the soft tissue, causing cellulitis. In severe cases, Staphylococcus 
aureus can spread to the bloodstream, causing a variety of illnesses such as septicemia, septic 
arthritis, endocarditis, meningitis, toxic shock syndrome, and osteomyelitis, among others (Kaiser 
2005). 
It can also lead to the formation of abscesses in the lungs, spleen, liver, and kidneys. When it enters 
the body, Staphylococcus aureus bacteria resist engulfment by leukocytes and inhibit the access of 
phagocytes to the area of infection (Kaiser 2005). The bacteria produce a protein A, which binds to 
the part of the antibodies that would typically bind to receptors on phagocytes, preventing the 
antibodies from attaching the bacteria to the phagocytes (Kaiser 2005). The bacteria cells also 
produce cytotoxins, which are toxic for leukocytes, macrophages, fibroblasts, erythrocytes, and 
platelets (Kaiser 2005). Staphylococcus infections are usually treated with the antibiotics 
Vancomycin, Oxacillin, or other penicillinase-resistant Penicillins. However, Staphylococcus 
aureus are becoming increasingly resistant to these antibiotics and the results can be fatal (Kaiser 
2005). 
 
Figure 8: Staphylococcus aureus bacteria (Carr, 2001). 
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Today, 52 percent of S. aureus isolates are multidrug resistant, meaning that the strain is resistant to 
three or more classes of antimicrobials. Furthermore, 96 percent of S. aureus isolates are resistant 
to at least one type of antimicrobial (Waters et. al. 2011). As cases of S. aureus become 
increasingly common, the frequency of antimicrobial resistance will continue to rise. This is 
particularly worrying, as the rate at which new antimicrobials are being developed is steadily 
decreasing. If this pattern continues, there will be more and more S. aureus infections that are 
impossible to treat, leading to an increase in mortality due to S. aureus infections. 
 
Methicillin-resistant Staphylococcus aureus 
 
MRSA stands for Methicillin-resistant Staphylococcus aureus. This particular type of bacteria is 
multiresistant, meaning the bacteria are resistant to a variety of antibiotics. MRSA bacteria are 
resistant to the ß-lactam category of antibiotics, which include Methicillin, Oxacillin, Penicillin, 
and Amoxycillin (Definition 2010).  
There are many mechanisms, which allow these bacteria to develop multi-drug resistance. For 
example, MRSA bacteria began to exhibit resistance to the antibiotic Vancomycin in 1997. This 
resistance is thought to have been acquired through the thickening of the bacterium’s cell wall due 
to an accumulation of cell wall fragments, which are able to bind Vancomycin extracellularly 
(Tenover 2006). 
MRSA bacteria have evolved resistance to ß-lactams by producing ß-lactamase enzymes (Sridhar 
2009). MRSA bacteria are colonized in the nose of 2% of people. This means that the bacteria are 
present, but do not cause infection (Definition 2010). Most MRSA infections are skin infections, 
but like other types of Staphylococcus aureus, MRSA can cause a variety of severe complications 
within the body. Also, it is imunosuppressed patients, such as hospitalized individuals, who are 
particularly susceptible (Definition 2010). 
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MRSA has evolved from several waves of resistance in Staphylococcus aureus bacteria, which 
have occurred since shortly after the beginning of antibiotic use. Staphylococcus aureus first 
developed resistance to penicillins in the mid-1940s, by producing a plasmid-encoded penicillinase, 
which hydrolizes the ß-lactam ring of the penicillin (Chambers, DeLeo 2009). 
This penicillin resistance brought on a pandemic, which slowed with the introduction of 
Methicillin. The first reports about methicillin-resistance, came in 1961. The gene responsible for 
methicillin-resistance, mecA, functions on a broad spectrum, allowing the bacteria to become 
resistant to all ß-lactam antibiotics (Chambers, DeLeo 2009). 
By the mid-1980s, MRSA was again a pandemic leading to the overuse of Vancomycin, which was 
the last available antibiotic that MRSA was susceptible to. This led to an extreme selective 
pressure, and eventually to vancomycin-resistant strains of MRSA (Chambers, DeLeo 2009). 
 
 
Figure 9: Percent resistance of MRSA bacteria in the United States. (Center, 2010) 
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MRSA is becoming an increasingly large problem in many areas in the western world. According 
to Figure 9, it can be seen that in 50.63% of MRSA colonies exhibited drug resistance in the United 
States in 2010. This is of grave concern, as it poses a huge threat to those particularly susceptible to 
the bacteria, such as hospitalized persons. In Figure 10, it can be seen that there has been a dramatic 
increase in the amount of MRSA cases the last 9 years in Denmark. This shows that MRSA is a 
growing problem in Europe, as well as in the United States. 
 
Figure 10: Number of MRSA cases in Denmark, by year (DANMAP, 2011). 
Antibiotics 
 
Antibiotics, often referred to as antibacterial, are compounds that fight against any sort of 
pathogenic bacteria. Antibiotics can be produced from microorganisms, e.g. Penicillin that is 
produced by Phenicillium fungi as well as chemically from C16H18N2O5S and other compounds 
produced semi synthetically.  
Over all, there are two modes of action by which antibiotics act on bacteria. Antibiotics that exert 
bactericidal activities and kill the bacteria, and bacteriostatic antibiotics that inhibit bacterial 
growth. 
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History 
 
Work on antibiotics began in the late 1800’s. In 1890, Joseph Lister made the first antibiotic that 
was used in the hospitals, but lately it was observed that the drug did not work most of the time. 
Then, in the 1928 Sir Alexander Fleming came up with a drug called Penicillin that revolutionized 
the work in the field of antibiotics. 
The discovery of penicillin itself was very interesting. Fleming came back from a holiday and 
started examining his plates where he had been working with Staphylococcus aureus. Due to 
contamination in his laboratory, a mold called Penicillium chrysogenum was growing on the agar 
plates. Fleming noticed that around where the mold had grown, there was no bacterial growth. This 
was the first discovery of the antibiotic effects that this mold had. He then set two of his assistants 
to separate pure penicillin from the mold juice. This drug, called Penicillin, was used in World War 
2, which cured many infections on soldiers wounded in combat (Bellis, n,d). 
For Fleming’s work in the field of medicine, he was awarded the Nobel Prize in ‘Physiology or 
Medicine’ in 1945. Later on, many chemists and surgeons carried forward with the work that 
Fleming had started, which paved way to the many improvements in the antibiotic field. 
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Classes of antibiotics 
 
There are many classes of antibiotics as seen in Table 1. 
Table 1: Major classes of antibiotics: 
Aminoglycosides Ketolides 
β-lactams 
• Penicillins 
• Cephalosporins 
• Carbapenems 
• Monobactams 
Lincosamides 
Macrolides 
Oxazolidinones 
Streptogramins 
Sulphonamides 
Flouroquinolones Tetracyclines 
Glycopeptides  
 
 Penicillin and mechanism of action 
Penicillin is a bactericidal antibiotic from β-lactam family of antibiotics. It is the most common 
type of antibiotic used among those suffering from any sort of infection. It slows down the 
synthesis of the bacteria cell so that the wall of the cell is thin and weak. This leads to the breaking 
of the cell wall when the bacteria try to grow. The wall is not strong enough to handle the pressure 
and the cell bursts. Some penicillin is of narrow spectrum and some of broad spectrum (Olsen, 
Inge. 2007). Penicillin is usually used for treatment of Gram-positive bacteria. 
 
 
 
Figure 11: Structure for one of the Penicillin antibiotic groups. 
http://drpinna.com/resveratrol-what-is-it-5837/penicillin-core1-2 (24/10/2012) 
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 Ampicillin and mechanism of action 
Ampicillin is from the β-lactam family of antibiotics, which tackles both Gram-positive and Gram-
negative bacteria. It differs from penicillin in its structure only due to the presence of an amino 
group. It is used to treat bacterial infections. They stop bacteria from multiplying by preventing 
bacteria from forming the walls that surround the cells. The walls are necessary to protect bacteria 
from their environment and to keep the contents of the bacteria cell together. Bacteria cannot 
survive without a cell wall (Oqbru, 2009). 
 
Figure 12: Structure for one of the Ampicillin groups. 
http://www.chemspider.com/Chemical-Structure.6013.html (03/12/2012) 
 
 Macrolides and mechanism of action 
Macrolides are another type of antibiotic that can be used as an alternative for those suffering from 
any sort of allergies to penicillin. They make a bond with the ribosome of the bacteria, which slows 
down the protein synthesis of bacteria. Therefore, macrolides have bacteriostatic effect (Olsen, 
Inge. 2007). 
 
 
 
 
 
 
 
Figure 13: Structure for one of the Macrolide groups. 
http://textbookofbacteriology.net/antimicrobial_4.html (24/10/2012) 
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 Tetracyclines 
Tetracycline is a broad spectrum antibiotic which was discovered in the 1940s and thanks to the 
favorable antimicrobial properties of these agents and the absence of major adverse side effects; 
they have been used extensively in the therapy of human and animal infections. (Chopra, 2001). 
Tetracycline is used to treat bacterial infections including pneumonia and other respiratory tract 
infections, acne, infections of skin, genital and urinary systems, and the infection that causes 
stomach ulcers (Helicobacter pylori). Furthermore they are added at sub therapeutic levels to 
animal feed to act as growth promoters in some countries including the United States. 
It may also be used as an alternative to other medications for the treatment of Lyme disease and for 
the treatment and prevention of anthrax (after inhalational exposure). It works by preventing the 
growth and spread of bacteria. These antibiotics will not work for colds, flu, or other viral 
infections. (U.S. National Library of Medicine, 2012) 
Tetracycline is a polypeptide in nature and has a tetracene ring structure. Tetracycline blocks 
bacterial cell growth by inhibiting the protein synthesis. It is well established that tetracycline 
inhibits bacterial protein synthesis by preventing the association of RNA with the bacterial 
ribosome, preventing the production of specific polypeptides. (Chopra, 2001) 
For the previous to take place, the antibiotic has to be able to get across the membranes, depending 
on which organism is being targeted; Gram-positive or Gram-negative. Tetracycline is able to 
penetrate the membrane of bacteria by binding with positively charged cat ions of magnesium. 
Tetracycline has the ability to chelate calcium and therefore prevent its absorption. Therefore, its 
use leads to calcium deficiency. It is also capable of binding to the calcium in teeth, thereby 
staining it. 
 
 
 
 
 
 
Fall Semester [ANTIMICROBIAL RESISTANCE] 
 
1st Semester project Page 23 
 
Tetracycline drugs such as Doxycycline have been used as a prophylactic drug for anthrax as well 
as for the bubonic plague. Systemically, Tetracycline is useful for the treatment of infections of the 
respiratory tract, urinary tract and the gastrointestinal tract. They are especially useful in patients 
who are hypersensitive to β-lactams and macrolides. 
 
 
Figure 14: Structure for one of the Tetracycline groups. 
http://www.chem.harvard.edu/groups/myers/page2/page4/page4.html. (03/12/2012) 
The high resistance values found both in Europe and United States have limited the use of 
Tetracycline for the treatment of human infections. However it is still used for a wide range of 
infections (Figure 15). 
 
Figure 15: Applications of Tetracycline. (Chopra, 2011) 
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There is no doubt that the use of Tetracycline clinically, and as a growth promoter and prophylactic 
in the animal and agriculture industry, has led to the creation of a selective pressure that is 
translated in resistant strains of bacteria that were once susceptible to the antibiotic. 
As early as 1960 there were numbers of resistance to Tetracyclines in hospitals, they found 
resistance levels as follows:  
Table 2: Resistance levels in 1960 (Sabath, 1969). 
S.aureus 38% 
E.coli 61% 
Klebsiella spp. 62% 
Enterobacter spp. 58% 
Proteus spp. 91% 
Serratia spp. 97% 
 
The low price of tetracycline makes it a widely used antimicrobial, especially in developing 
countries. A study carried out by (Acar, 1997), shows high levels of resistance for S. pneumonia to 
Tetracycline in Brazil, Mexico and South Africa. However, the same or higher levels were shown 
in regions were the sales of tetracycline has diminished, such as the United States and Europe. This 
can be seen in two ways, the first being that the specific r genes for Tetracycline are stable 
regardless of the reduction of the selective pressure. This also might relate to the ability of Gram-
positive bacteria to acquire and maintain multiple r genes. 
More importantly, the resistance shown by a number of zoonotic pathogens such as Salmonella 
serovars, Campylobacter spp., and Yersina spp and commensals such as E. coli and Enterococci is 
present in both the animal and human ecosystems (Chopra, 2011). This in practice generates a high 
risk for humans since the infection can be food-bourne. 
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 Chloramphenicol and mechanism of action 
Chloramphenicol is a broad-spectrum antibiotic, which is used to treat the infections caused by 
Gram-positive and Gram-negative bacteria. It is considered to be a strong antibiotic with some 
serious side effects. This is why it is only prescribed when other agents fail to cure. It prevents the 
elongation of protein chains, which inhibits bacterial growth. It is widely used as an agent that 
fights typhoid and as eye drops when the outer layer of eye turns pink due to bacteria.  (Houghton 
Mifflin Company, 2004). 
 
Figure 16: Structure for one of the Chloramphenicol groups. 
http://chemistry.about.com/od/factsstructures/ig/Chemical-Structures---C/Chloramphenicol.-e8H.htm (24/10/2012) 
 
 Cephalosporin and mechanism of action 
Cephalosporin is one of the most widely used antibiotics. Its structure and mode of action is very 
much similar to the one of the penicillin. It has β-lactam ring and it is bactericidal, meaning it kills 
bacteria. The mode of action of this antibiotic involves disruption of the synthesis of the 
peptidoglycan layer of bacterial cell walls. The 1
st
 generation of cephalosporin works against the 
Gram-positive bacteria, while the 2
nd
 generation works against the Gram-negative (Beers, 2003). 
 
Figure 17: Structure for one of the Cephalosporin groups. 
http://withfriendship.com/user/mithunss/cephalosporin.php (24/04/2012) 
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 Streptomycin and mechanism of action 
Streptomycin is an antibiotic, which is used as a remedy for tuberculosis. It is bactericidal and 
cannot be given orally but as an injection in the muscles. It is a broad-spectrum antibiotic, which 
attacks both Gram-positive and Gram-negative bacteria. It combines with the small subunit of the 
ribosomes, interfering with protein synthesis. As a result, the bacteria die. 
 
Figure 18: Structure for one of the Streptomycin groups. 
http://pubchem.ncbi.nlm.nih.gov/summary/summary.cgi?cid=19649 (24/10/2012) 
 
Figure 19. Most common antibiotics and its mode of action Davies, 2010: 418. Print. 
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Spectrum of antibiotics 
 
When we refer to the spectrum of antibiotics, it means the types of bacteria being targeted. For 
those having a narrow spectrum, only specific kinds of bacteria will be attacked. For those with a 
broader spectrum, multiple types of bacteria will be attacked. 
Generally, narrow spectrum is used. A doctor will usually prefer to treat the patient for the specific 
infection using a narrow spectrum antibiotic, not to harm the natural and beneficial bacteria that 
exist in the body. As the spectrum grows bigger, it is likely that healthy bacteria are also being 
annihilated. 
A problem that arises while using an antibiotic is the resistance of bacteria towards it. This 
phenomenon occurs when some individuals from the bacteria population carry an allele that codes 
for resistance. The bacteria that have this gene are given an advantage when introduced to 
antibiotics, and are then favored through natural selection. By these means, a bacteria population 
can quickly evolve to be resistant. These genes can also be passed from one bacterium to another. 
The problem increases when bacteria are treated with antibiotics repeatedly. The bacteria 
population becomes increasingly resistant and eventually the antibiotic is of no use. The residual 
resistant bacteria are difficult to treat. 
Negative effects of antibiotic treatment 
 
One of the negative effects of using antibiotics is that when bacteria are treated with the same type 
of antibiotic repeatedly, they may develop resistance to that antibiotic, and can no longer be killed 
with it. Another problem arises when bacteria that are beneficial to the body are killed by the 
antibiotic in the process of curing an infection (Olsen, 2007). This mostly happens when broad 
spectrum antibiotics are used. This can impair many bodily functions and yield a variety of 
negative side-effects. For example, some people may develop allergies after being treated with 
penicillin. 
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Antimicrobial resistance 
 
The term antibiotic resistance, also referred to as antimicrobial resistance or drug resistance, is the 
capability acquired by a bacteria to resist the action of a certain drug to which it was previously 
sensitive. 
 
Since the introduction of the first antimicrobial, the problem of resistance has been a major concern 
within the scientific field. Several years before penicillin was first used, a bacterial penicillinase 
was identified, which meant that there was an intrinsic resistance gene, or r gene, that was able to 
express and reduce the effect of the antimicrobial (Davies, 2010). This, in the light of recent 
studies, shows that a large number of antibiotic r genes are components of natural microbial 
populations (D’ Costa et.al, 2006). 
 
To understand the complexity of the resistance problem, it is imperative to consider that, as any 
other living organism, bacteria have an astonishing ability to evolve and adapt to their environment. 
Furthermore, gene transfer is a universal property of bacteria that has occurred throughout millions 
of years of evolution. It is important, however, to acknowledge the fact that antimicrobial resistance 
is a response to selective pressure of antibiotic use and disposal, which is much more intense and 
favors selection in hostile environments (Davies, 2010). 
 
A very good example that helps to understand the resistance problem in the modern world, is to 
look at Mycobacterium tuberculosis (MTB), which is an archetypical human pathogen that has 
evolved with the human race and currently infects as much as one-third of the world population. M. 
tuberculosis is treated with a cocktail of anti- TB drugs that have shown to be effective. However in 
the last decade some strains that show resistance to four or more of the front line treatments 
(extremely drug-resistant [XDR] strains) have appeared and spread rapidly (Shah, 2007). 
 
There is a direct relationship between the generation of environmental reservoirs of antibiotic 
resistance and human activity. Less than half of all the commercially produced antibiotics are used 
for human therapy, which means that the rest is used in other activities such as growth promotion, 
animal therapy, aquaculture use, and pest control in agriculture. 
Fall Semester [ANTIMICROBIAL RESISTANCE] 
 
1st Semester project Page 29 
 
The principal goal in the use of any antimicrobial agent or antibiotic for the treatment of infections 
is the eradication of the pathogen as quickly as possible with minimal adverse effects on the 
recipient (Capitano, 2001). In order for this to happen, there must be a series of basic conditions. 
First, the antibiotic should be able to bind to a specific binding site on the microorganism in order 
to be capable of disrupting a biochemical process that should be critical for the bacteria to survive. 
Second, the concentration of the antibiotic must be sufficient to occupy a significant number of 
these active sites in the microorganism. Lastly, the agent should be capable of occupying this active 
site for an adequate period of time. 
 
The relationship between the antibiotic concentration and the time that the concentration remains at 
these active sites can be seen as a concentration- time curve (Cp × time = AUC) (Nightingale, 
Grant, 1999, 2001). The AUC index can be used as a guide to know the efficiency of the 
antimicrobial agent against the microorganism. This can also be referred to as the minimum 
inhibitory concentration, or MIC. The AUC/MIC index represents the minimum concentration of 
antibiotic needed to interfere in the life cycle of the microorganism.  
 
 
Figure 20: Concentration–time curve showing the area under the time–concentration curve (AUC) (shaded area)(Mouton et al, 
2011) 
When antimicrobials are used as growth promoters in agriculture and as prophylactics in human 
and veterinary medicine, there is a risk of not using the adequate AUC/MIC index. Therefore, 
resistance can develop by those strains that have a higher MIC, and pass it on by genetic way. 
 
The resistance problem can be seen simplistically as an equation with two main components: the 
antibiotic or antimicrobial drug, which inhibits susceptible organisms and selects the resistant ones, 
and the genetic resistance determinant in microorganisms, selected by the antimicrobial drug (Levy, 
2004). 
Fall Semester [ANTIMICROBIAL RESISTANCE] 
 
1st Semester project Page 30 
 
Mechanisms of resistance 
 
It has been assumed that the acquisition of resistance was a demanding energetic process for the 
microorganism. This is true for some mutant strains that have limited growth under laboratory 
conditions. Thus, it was considered that multidrug- resistant strains would be unstable and short 
lived in the absence of selection (Andersson, 2006). However, in recent studies, a mutant, multi-
drug resistant strain of S. aureus in a patient treated with Vancomycin was reported (Mwangi, et al. 
2007). Insolates were sampled at frequent intervals over the course of 3 months and 35 mutations 
were identified. 
 
The function of the mutations is not understood, but it shows that regardless of the energy cost, the 
microorganism is capable of change and survival in vivo by mutating.  It also makes clear that there 
is a need for detailed analyses of resistance development in situ. 
 
There is still a lack of knowledge in how the bacteria adapt to their environment, and how the 
adaptation of the microorganism helps it to generate resistance to one or more antimicrobials. 
However, the resistance mechanisms are understood and can be differentiated as follows: 
 
Genetic Resistance 
 
Development of antibiotic resistance tends to be related to the degree of simplicity of the DNA 
present in the microorganism becoming resistant, the ease with which it can acquire DNA from 
other microorganisms, and the relative easiness of which genes are shared within a colony (Alanis, 
2005). Horizontal Gene Transfer (HGT) plays a very important role in genome evolution and in 
how an r gene is given to new cells.   
 
Even though Gram-positive and Gram-negative show clear differences in structure and function, 
the ability to acquire r genes and promote their transmission is a shared property.  
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Resistance can be intrinsic to a certain kind of microorganism, where the mutation of a specific 
gene occurs without the selective pressure of an antimicrobial. It can also be transmitted to others 
by those that already have a genetic determinant that is able to express itself. The second scenario is 
by far the most common way to acquire resistance. 
 
For antibacterial resistance to occur, certain conditions must be fulfilled. The presence of the 
antimicrobial that is capable of negatively affecting a homogenous population of certain bacteria is 
crucial, as well as the presence of at least one individual within the population that carries a gene 
coding for resistance to the antimicrobial. In a situation containing these two factors, the 
susceptible population of the bacteria dies, while the resistant strain survives and passes their 
resistance genes on to the next generations of bacteria. 
 
The genes that code for resistance are usually located in specialized fragments of DNA called 
transposons. The transposons (transposable elements) move within a genome by means of a DNA 
intermediate. Transposons can move by a “cut and paste” mechanism, which removes the element 
from the original site, or by “copy and paste” mechanism, which leaves a copy behind, in order for 
this to take place an enzyme (transposase) must be present, the enzyme is generally encoded by the 
transposon (Campbell, 2002). 
 
A major part of the resistance genes present on transposons, plasmids and chromosomes is 
integrated into DNA elements called class 1 integrons. These genetic elements were first identified 
and characterized in 1987(Hall, Collis, 1998). Integrons are not themselves mobile genetic 
elements but become so in association with a variety of transfer and insertion functions (Holmes 
et,al. 2003).  These genetics elements are site- specific elements capable of integrate and express 
genes contained in cassette like structures. Most of todays identified cassettes encode resistance 
genes, however the origin of integrons is not known. (Davies, 2010) 
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Class 1 integrons are associated with hospital environment multi resistance, and there is no data at 
the moment on whether or not there is prevalence of these genetic elements in the community 
(Hall, Collis, 1998). However, there is suggestion of a strong linkage between the acquisition of 
integrons in the community and food producing animals, which suggest that integrons are 
worldwide spread and their acquisition is via the food chain.  
 
Integrons were thought to be exclusive to Gram-negative bacteria, however Nandi (2004) 
discovered the presence of integrons in Gram-positive bacteria. There has not been established the 
relationship between these integrons present in Gram-positive bacteria and antibiotic resistance. 
 
Figure 21 shows the integron structure and gene capture mechanism. The structure consists of an 
integrase (Int) with the Pint and PC promoters in the 3’ end of the gene, with its associated cassette 
attachment or insertion site (attI). Three classes of integrons have been identified that differ in their 
integrase genes (Davies, 2012). 
 
Figure 21: Integron cassette. (Davies, 2010) 
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The most common mechanisms of genetic transfer are: 
 
1. Conjugation 
This is the most common mechanism of transmission of resistance in bacteria. The resistant 
bacterium creates a hollow tubular structure, a pilus that connects with the non-resistant bacteria 
and passes on the resistance plasmids, which are circular fragments of DNA that can replicate 
independently from the bacterial chromosome. A plasmid has only a small number of genes; these 
genes may be useful when the bacterium is in a particular environment (Campbell et.al, 2002), such 
as selective pressure (Figure 24). 
 
Figure 22: Bacteria and its plasmid. 
(Moran, 2009) 
2. Transformation 
This usually occurs when a bacterium breaks apart and the entire DNA, naked DNA, is taken by the 
nearby bacteria into their cytoplasm, where this DNA gets incorporated into the host DNA. 
 
 
3. Transduction 
This mechanism occurs via the use of a vector by a bacteriophage, a virus capable of infecting 
bacteria. The virus containing the gene that codes for antibiotic resistance infects a new bacteria 
cell. Thus, the infected bacteria carry the new gene. The virus also introduces its own viral DNA, 
forcing the cell to create more copies of the infecting virus until its dies and liberates the new 
bacteriophages that carry on infecting new cells. 
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Figure 23: Most common mechanisms of genetic transfer  
(Todar, 2009) 
 
Figure 24: Horizontal Gene Transfer (NIAID). 
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Biological mechanisms of resistance 
 
Regardless of the way the resistant gene is transferred, the resistance is only going to take place if 
the gene is able to express itself and produce a noticeable negative effect in the action of the 
antibiotic. The biological mechanisms of resistance that the bacterial cell uses are: 
 
1. Antibiotic destruction or transformation 
The bacterium produces one or more enzymes that chemically degrade or modify the antimicrobial, 
making it inactive against the bacteria (Alanis et al, 2005). Several antibiotics have β-lactam, such 
as penicillin, as part of their structure, which inhibits bacterial cell wall synthesis. This kills the 
bacteria, but some resistant strains of bacteria can produce β-lactamases, an enzyme that breaks 
open the ring structure, deactivating the antibacterial properties. 
 
2. Antibiotic active efflux 
This mechanism only concerns those antibiotics that act inside the bacterial cell. The resistant cell 
is capable of creating an active transport mechanism that pumps the antimicrobial outside the cell 
until the concentration of the antibiotic is less than that necessary to cause a threat. 
 
3. Receptor modification 
In order for an antimicrobial to be a detriment to a bacteria population, it must find a binding spot 
on which to work. However, some resistant bacteria have the ability of altering these sites. 
Therefore, the antimicrobial has no effect at all. PBP’s, penicillin-binding proteins, are usually 
modified in penicillin-resistant bacteria. 
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4. Development of site of action by pass mechanism 
 
 
Figure 25: Modes of action and resistance mechanisms of antibiotics (Davies, 2010: 418. Print.). 
 
When antibiotics are used in humans, they create a selective pressure, especially in broad-spectrum 
antimicrobials. This means that the chances of creating resistance are greater. Thus, most of the 
susceptible bacteria in the host will die and the resistant treads are capable of survival, despite the 
presence of the antibiotic. Therefore, the host becomes a reservoir of resistant treads that are 
reproducing, and since under optimal conditions bacteria have a generation time of minutes to 
hours, this allows for new mutations and selection. This represents a significant threat in hospitals 
where immunosuppressed patients, such as newborns, are at risk. 
 
Resistance is not the same for every bacterium and there are different levels of resistance. For 
instance, F. Baquero defines a low-level resistant organism as an organism with an ‘MIC higher 
than is common for the susceptible population, devoid of any acquired resistance mechanism’ 
(Baquero, 2001). 
 
Unfortunately, many of the bacterial pathogens associated with epidemics of human disease have 
evolved into multidrug resistant (MDR) forms due to antibiotic use, and the ‘superbugs,’ microbes 
responsible for enhanced morbidity and mortality, that are found these days are resistant to the 
antibiotic class specifically recommended for their treatment. This leads to reduced options for 
treatment and more costly hospital bills (Davies, 2010). 
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Alternatives: Antimicrobial Peptides 
 
Introduction to Antimicrobial Peptides 
In the past couple of decades antibiotic efficiency has been seriously diminished. Bacteria are 
developing resistance to drugs, and have created obstacles for the treatment of illnesses. In the past, 
new antibiotics were created to counter the resistancy of the bacteria, but now the production of 
new antibiotics has also been diminished due to the difficulty and economic costs. 
We now face bacteria that are resistant to many of our antibiotic options, and with the very slow 
and almost non-existence production of new antibiotics alternatives are needed to protect humans 
from pathogenic invasion. One such alternative is found among all classes of life, and naturally 
helps fight bacteria, fungi, and viruses; in addition, antimicrobial peptides (AMPs) are thought to 
have direct antimicrobial and immunomodualtory properties that help get rid of infection and heal 
wounds. 
Antimicrobial peptides are very diverse and consist of many different groups; so they are organized 
into three groups by their origins. These groups are eukaryotic AMPs, bacteriocins, and phage-
encoded AMPs, and are found in all forms of life including humans. These antimicrobial peptides 
have different structures which, also effects their antimicrobial activity and effectiveness. The four 
main structures are -helical, -sheeted, loop structure, and extended structure; however, there are 
other secondary structures and even combinations such as, -helical and -sheeted structures 
(Jenssen et al. 2006) (Figure 26).  
 
Figure 26: Antimicrobial Peptide Structure. (A) -sheeted (B) –helical (C) extended structure (D) loop structure. 
(Powers, Hancock, 2003)  
 
Fall Semester [ANTIMICROBIAL RESISTANCE] 
 
1st Semester project Page 38 
 
Eukaryotic AMP’s are cationic, positively charged, which property allows them to interact with the 
bacterial anionic, negatively charged, membrane. In addition they are amphipathic; contain both 
hydrophilic and hydrophobic parts. This means that the antimicrobial peptide has a part that can be 
dissolved by lipids, and one that can be dissolved by water (Parisien et al. 2007). These 
mechanisms allow AMPs to attach to the cell wall and create pores on the membrane for increased 
permeability and loss of cell content (Parisien et al. 2007). 
Most known classes of AMPs are defensins, cathelicidins, and histatins. Defensins are the most 
abundant family of AMPs, and are characterized by their six cysteine residue molecules, which 
form a structure with disulfide bridges between two cysteine molecules. Defensins help protect 
against pathogens and kill bacteria, and they also help with the innate immune system. For 
example, HBD-3, a -human β defensin, shows strong antibacterial activity, salt-insensitiveness, and 
low toxicity for the host HBD-3 showed to be active against both Gram-positive and Gram-
negative bacteria (Batoni et al. 2006).  
Although not researched as much as defensins, cathelicidins seem to be strong alternatives for 
antibiotics with their variety of sizes, sequences, and structures. Cathelicidins all have a N-terminal 
cathelin domain and a C-terminal cationic antimicrobial domain that becomes active after 
separation. Just like defensins, cathelicidins have important roles within the innate immune system 
and diverse antimicrobial activities; however, one special thing about cathelicidins is that they can 
bind to endotoxins and stop their harmful effects (Parisien et al. 2007).  This could be extremely 
helpful for Gram-negative bacteria that carry lipopolysaccharides, which is an endotoxin that is 
released when the cell wall begins to breakdown. The only human cathelicidin found is called LL-
37, and is most abundant in neutrophils and various epithelial cells (Durr et al. 2006). In addition to 
its antimicrobial activity, it also seems to be a promoter of healing damaged tissue and skin 
(Heilborn et al. 2003).  
In 1925 André Gratia discovered bacteriocins, and more specifically colicin, which killed certain 
strains of E. coli. Bacteriocins are another type of AMPs that come from bacteria; to be more 
specific, 99% of bacteria produce at least one type of bacteriocin, which makes them very specific.  
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This means that the bacteriocins only work well with the closely related bacteria strain (Kirkup Jr. 
2006). Bacteria have bacteriocins because even for bacteria there is competition for food and 
survival. Because bacteriocins have such a narrow spectrum of activity they have been divided into 
Gram-negative and Gram-positive bacteriocins; in addition, colicin is used for E. coli, and 
lantibiotics for S. aureus. 
Colicins are made by E. coli which they also kill to reduce bacterial competition. The producing 
strains of certain colicins have an immune gene that protects it from the effects of the AMP; 
however, susceptible or sensitive E. coli bacteria are vulnerable to the effects of colicin (Parisien et 
al. 2007). Colicins can kill bacteria in different ways that include but not limited to: pore formation, 
DNases activity, and RNases activity (Gavioli, 2010).  
Table 3: Antimicrobial Peptide Sequences. The letters in the structure section denote amino acids; details in appendix. (Hancock, 
chapple, 1999) 
Peptide Function Structure 
Gramicidin S 
Destroys ion 
gradient 
Cyclic (LOVPF
d
LOVPF
d
) 
Bacitracin 
Inhibition of 
peptidoglycan 
synthesis 
Cyclized I(C)LE
d
I(KO 
d
IFHD)D
d
-NH2 
Polymyxin B 
Alters membrane 
structure; osmolysis 
Cyclized isooctanoylBTBB(BF
d
LBBT) 
Rabbit α-defensin 
(NP-1) 
Permeablizes 
membrane 
  VVC1AC2 RRALC3LPRERRAGFC3 
RIRGRIHLC2 C1 RR 
Human β-defensin 
1 
Membrane 
disturbance; 
cytoplasmic leakage 
DHYNC1VSSGQC2LYSAC3PIFTKIQGTC2Y
RGKAKC1C3 K 
Crab tachyplesin 
Permeablization of 
membrane 
RRWC1FRVC2YRGFC2YRKC1 R 
Cattle bactenecin 
Inhibit cellular 
respiration  
RLC1 RIVVIRVC1 R 
Silk moth cecropin 
A 
Lysis of membrane 
KWKFKKIEKMGRNIRDGIVKAGPAIEVIG
SAKAI 
Cattle indolicidin 
Multiple; inhibition 
of DNA synthesis 
ILPWKWPWWPWRR 
Bacterial nisin 
Depolarization; 
inhibition of cell 
wall synthesis 
IXA1IULA1Z2PGA2KZ3GLAMGA3NMKZ4AZ
5A4HA5SIHVUK 
 
Fall Semester [ANTIMICROBIAL RESISTANCE] 
 
1st Semester project Page 40 
 
Polymyxin B is a lipopeptide and contains a polycationic peptide ring and a tripeptide side 
chain with a fatty acid tail and comes from Bacillus polymyxa bacterium, which means it’s 
categorized as a bacteriocin. Referring to Table 3 the reader can see the structure of the 
antimicrobial peptide and it’s mechanism of action. To be more specific, Polymyxin B only works 
on Gram-negative bacteria because it binds to LPS where through self-promoted intake breaches 
the outer membrane, then once inside, the AMP binds to the membrane and makes it permeable, 
this allows increased intake of water and results in osmolysis and cell death.  
Today, polymyxin B is used only as a topical because it is very toxic; one example is its use in 
Neosporin. It is important to know that the d subscript is to denote the d-enantiomer while all the 
others that don’t have a subscript symbolize the l-enantiomer. (See description in Appendix). 
Referring to Figure 27 one can see the chemical structure and the fatty acid depends on the 
components of polymyxin B which is polymyxin B1 to B4 (Zavascki et al. 2007).  
 
Figure 27: Structure of polymyxin B. Fatty acid: 6-methyloctanoic acid for polymyxin B1, 6-methylheptanoic acid for B2, octanoic 
acid for B3 and heptanoic acid for B4. Thr, threonine; Leu, leucine; Dab, a,g-diaminobutyric acid; Phe, phenylalanine; where a 
and g indicate the respective amino group involved in the peptide linkage (Zavascki et al., 2007). 
 
The term Lantibiotics (lanthionine-containing antibiotics) stems from the fact that they contain the 
amino acid lantine, and are made by lactic acid bacteria (LAB), Staphylococcus, and other Gram-
positive bacteria (Parisien et al. 2007). There are two types of Lantibiotics based on the structure: 
type A which is flexible, long, and kills bacteria by forming pores, and type B which are rough, 
globular, and usually kills by inhibiting biosynthesis of the cell wall (Brötz, 2007). The most 
important lantibiotic is the type A antimicrobial peptide Nisin, which for now has been used as a 
food preservative (Parisien et al. 2007). 
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The last type of AMP is phage encoded AMPs. There are two types of phage encoded AMPs; the 
first being phage encoded lytic which has three different classes. The first class is recognized as E 
and is composed of φX174 class; the L lytic factor is composed of MS2/GA classes of RNA 
phages, and the last is the A2 lytic factor composed of RNA Qβ/SP. All three lytic factors have 
similar mechanisms of action, which is the bacteriolysis of bacteria at certain time (Parisien et al. 
2007). 
Phage encoded lytic factors use nonenzymatic mechanisms with bacteria; meaning that they don’t 
use enzymes. E and L genes change the membrane proteins while A2 genes bind to the sex pilus of 
the bacteria. More specifically, protein E inhibits the phosphor-MurNAc-pentapeptide translocase 
(MraY) protein responsible for the biosynthesis of the peptidoglycan layer (Mendel et al. 2006). 
Much more researched has been done on the E protein while L and A2 research has been minimal. 
The second type is phage tail complexes that are made up of large amount of peptide subunits. 
These peptides bind to specific receptors on the outside, and have the ability to pierce through the 
outer membrane on Gram-negative bacteria. In addition, the AMP can also pierce the 
peptidoglycan layer, and then inject the phage genome into the bacteria (Parisien et al. 2007). For 
example, the tail of the bacteriophage T4 can pierce the cell membrane of E. coli, and then it 
contains the lytic activity to hydrolyze the peptidoglycan layer. The antimicrobial effects of phage 
tail complexes are still being researched; however, they still contain the ability to bypass the cell 
membrane and wall of bacteria (Parisien et al. 2007) 
AMPs have the potential to do great things, but further research and funding is needed for them to 
become widespread. Their benefits are too great to ignore; for example, Nisin, a type A Lantibiotic, 
is the most commercially used AMP as a food preservative without a great increase of bacterial 
resistance (Delves-Broughton 2005). In addition, it is active at a low concentration and even works 
on drug-resistant strains. Eukaryotic AMPs have a broad spectrum of activity, and bacteriocins are 
nontoxic and specific; furthermore, both have strong antimicrobial activity. 
AMPs have shown to be strong against bacteria, and because of the variety of structures and 
mechanisms of action have many different possibilities and great potential. Human testing using 
bacteriocins have even been used with positive results; however, the FDA (Food and Drug 
Administration) has yet to approve of any AMP’s (Parisien et al. 2007).  That is why antimicrobial 
peptides need to be researched and used in the future in place of antibiotics. 
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Mode of Action 
 
Antimicrobial peptides are shown to have two different modes of action when fighting bacteria, 
non-receptor mediated mechanism and receptor mediated mechanism. All antimicrobial peptides in 
some way interact with the membrane; when the AMP’s are at the membrane is where the 
difference occurs. 
However, first the antimicrobial peptide must select and attach to the bacteria, which it is able to do 
because of its electrostatic and amphipathic properties. AMP’s are usually cationic and are attracted 
to the anionic membranes of bacteria. AMP’s attack bacteria membranes because Gram-positive 
have teichoic acids which help increase the negatively charged membrane; in addition, Gram-
negative bacteria have lipopolysaccharides which also increase the already negative charged 
membrane. On the other hand, mammalian cell membranes are zwitterionic, emitting positive and 
negative charges (Shai, 2002). 
In summary, the reason why antimicrobial peptides attack bacteria cells and not host cells is 
because they are more attracted to the higher negative charged bacteria membranes rather than the 
neutral charge membrane of mammals. With non-receptor mediated mechanism the goal is the 
bacterial membrane.  
The amphipathic form is what allows the AMP to function as an antibacterial activity because it is 
the hydrophobic and hydrophilic parts that allow it to permeate the membrane (Shai, 2002). The 
hydrophobic region interacts with the lipid part of the membrane, while the hydrophilic part 
interacts with either the head of the phospholipid or the lumen, empty space, of the pore. 
The receptor-mediated mechanism is usually restricted to AMP’s that come from bacteria like 
bacteriocins and lantibiotics. For example, Nisin Z connects itself to the lipid II cell wall precursor, 
which is responsible for cell wall biosynthesis. The antimicrobial peptides that use the receptor-
mediated mechanism are composed of two regions: a receptor-binding domain, and a pore-forming 
domain. When the receptor-binding domain connects to the receptor the pore-forming domain is 
cleaved off and proceeds to permeate the membrane (Shai, 2002).  
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There are two different ways that AMP’s permeate through the membrane. Most AMP’s will form 
some sort of pore to travel through; however, some AMP’s will translocate, move from one place to 
another, through the phospholipid bilayer without disturbing the membrane. AMP’s kill the bacteria 
usually by permeablizing the membrane and causing lysis, rupture, that results in leakage of cell 
content or harmful materials getting into the cell; however, it has been proven that when a AMP 
translocates across the membrane it can cause failures to essential processes inside the cell such as, 
inhibition of DNA/RNA, protein, or cell wall synthesis, and few others (Jenssen et. al. 2006).  
There are a couple different types of models explaining how antimicrobial peptides work to 
permeablize the membrane, but before going into the models explaining how the AMP’s interact 
with the phospholipid membrane is important. With Gram-negative bacteria, AMP’s arrive at the 
outer membrane where they take part in a process called self-promoted uptake, which is the act of 
displacing either     or      on lipopolysaccharides and creating instability of the membrane 
and allowing AMP’s to pass through. Figure 28 illustrates the possible models of pore formation: 
(A) barrel-stave model (B) Carpet model (C) Toroidal model. Also Figure 28 is the process of 
translocation through the phospholipid membrane.  
The pore formations are based on -helical structures and not -sheeted structures because research 
and experiments are still needed to confirm it. Furthermore, uncertainty on the actual pore 
formations still lives because many factors come into play such as the concentration of the AMP 
and the possibility of multiple mechanisms of action (Jenssen et al. 2006). 
 
Figure 28: Antimicrobial peptide pore-formation. (A left): Barrel-Stave model. (B): Carpet model. (C): Torodial model (Haney, 
Vogel, 2009).  
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Discovery and Drug Development 
 
Since antimicrobial resistance has been greatly increased for the last many decades, one would 
believe that new antibiotic drugs would be developed as needed. But this is unfortunately not the 
case as seen in Figure 29. 
Since 1983-1987 where 16 new antibacterial drugs were approved for use, we are now at new low 
level record where only 2 new antibacterial drugs were approved in 2008-2012. 
One of the reasons for the lack of new antibacterial drugs, is that it approximately costs the 
pharmaceutical companies an average of $800 million to fully develop a new drug. (Collier, 2009). 
Not only is the development extremely expensive, but the process can also take up to 20 years 
before the new drug is approved and ready to be marketed (University of Arizona 20. December 
2012). 
Preclinical trials are the opening stages of the procedure, and involve two different things; 
determining the toxic and pharmacological effects on laboratory animals. 
The purpose of phase I, is to determine the metabolic and pharmacological effects on a small 
number of healthy volunteers, and to measure side effects. All of this helps in making a safety 
profile of the drug. 
Phase II is done on several hundred patients who have the associated disease, which the given drug 
is meant to treat. Data is being gathered on the effectiveness of the drug, and the short-term side 
effects are also being measured. If there is evidence that the given drug obtains some effectiveness, 
it is sent to Phase III for further testing. 
Phase III is the final testing which is done, before the new drug can be approved, and this process 
can take up to 4 years. The testing is done on up to several thousand patients, and include both 
controlled and uncontrolled trials. Further data about the effectiveness and side effects of the drug 
are measured before it can be approved. 
Phase IV is for post surveillance and to improve the safety profile of the drug. 
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Although no antimicrobial peptides have been approved by the FDA, several AMP’s show very 
promising results. Antimicrobial peptides are beneficial because of the rapid response time, the 
variety of possibilities, and strong antibacterial activity. The past 10 years drug development has 
dramatically decreased compared to the mid 1900’s. The medicinal community needs new 
antibiotics, and if no new antibiotics are created then an alternative is needed, especially for Gram-
negative bacteria. 
AMP drug development provides the broad spectrum antibacterial needed to treat the different 
types of bacteria; in addition, AMP’s attack general areas; the result being that bacteria don’t 
develop resistance as quickly (Jenssen et al. 2006). The increased interest of AMP’s has boosted 
research into the matter and caused the development of many different AMP’s and the creation of 
many different analogues. Finally, the use of AMP’s has shown to heal wounds, stop inflammation, 
and boost immunomodualtory functions (Jenssen et al. 2006).  
 
 
Figure 29: Antibiotic drug approvals (Howard, 2012). 
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Experiment 
Since the aim of this project was to see and compare the efficiency of conventional antibiotics and 
antimicrobial peptides, experiments were conducted in the laboratory with Tetracycline (Figure 
30), Ampicillin and Polymyxin B on Escherichia coli (strain MG1655) and Staphylococcus aureus 
(strain ATCC 29213). 
The experiment lasted one week, and was repeated the second week to be able to compare our 
results, and Polymyxin B was only tested in week two. 
 
 
Figure 30: Tetracycline being prepared. 
 
Method 
In the experimental procedures of this investigation, the minimum inhibitory concentrations (MICs) 
of two conventional antibiotics and one antimicrobial peptide (Polymyxin B) were tested. The 
effectiveness of all three antimicrobials was tested on class one E. coli and S. aureus bacteria 
strains 
In order to do the MIC testing, different concentrations of antibiotics were added to a bacteria 
culture, to determine the lowest concentration of the antibiotics and antimicrobial peptide needed to 
inhibit bacterial growth. 
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E. coli and S. aureus were the chosen bacteria types because they were readily available, and are 
relevant to the topic at hand, since both are causing problems due to multiresistance. Also, with 
these two bacteria types, a thorough analysis of the functions of the antimicrobials was gained, as 
one is Gram-positive and the other is Gram-negative. 
The procedure was carried out as follows; 
 
Day One 
Overnight Culture: 
An overnight culture of each bacteria type was prepared by adding a colony of bacteria from an LB 
plate to 5 ml of LB (Luria-Bertani) medium. This mixture was prepared in a glass tube, and 
incubated in a shaking water bath at 37ºC overnight. 
 
 
Figure 31: A bacteria and LB mixture beeing prepared overnight in a waterbath at 37ºC. 
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Day Two 
Achieving Optimal Density: 
In order to begin working with the bacterial suspension, an optical density of 0.4 had to be 
achieved. The OD600 of 0.4 was reached by incubating the suspension in a shaking water bath at 
37ºC and testing the OD every 25 minutes using a spectrophotometer. See more in appendix about 
optical density and spectroscopy.  
 
The overnight culture was diluted 100 times in an Erlenmeyer flask. This was done by adding 
500µl of the overnight culture to 50ml of LB medium. Then, this flask was placed in a shaking 
water bath at 37ºC. The OD600 was measured every 25 minutes using a spectrophotometer, until the 
OD600 was 0.4. This was done for both E.coli and S. aureus. 
 
Figure 32: The diluted overnight culture in a shaking waterbath at 37ºC. 
Dilution of Bacterial Suspension: 
After the OD600 of 0.4 was reached, the culture was then diluted 500 times, which was done by 
first diluting it 100 times, and then 5 times. To dilute the culture 100 times, 100μl of the culture 
was added to 10ml of LB medium. Then, 1ml of the diluted culture was added to 5ml of LB, in 
order to dilute the solution 5 times.  
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Preparations of Antibiotic Concentrations: 
To prepare the antibiotic solutions, different concentrations of antibiotics were prepared in 
Eppendorf tubes. In order to determine the concentrations, the formula             was used, 
where C1 is the initial concentration, C2 is the final concentration, V1 is the initial volume, and V2 is 
the final volume. 
1. 50μl of the 2mg/ml Polymyxin B stock solution was added to 450μl of water, to reach a 
concentration of 1mg/ml. 
2. Then, 500μl of water was added to this solution, bringing the concentration to 500μg/ml. 
3. Finally, 1μl of water was added to achieve the desired concentration of 250μg/ml. 
4. A series of concentrations were then achieved by taking 250μl from the first Eppendorf tube 
and adding it to a second tube, along with 250μl of water. Then, the same was done from 
the second tube to the third tube, and so on, until 7 tubes with different concentrations were 
prepared. 
5. Before taking solution from a tube, the tube was thoroughly shaken in order to ensure an 
even distribution of the antibiotic. 
 
Figure 33: Diluting bacteria to the right concentration. 
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The final concentrations were 250μg/ml, 125μg/ml, 62.5μg/ml, 31.25μg/ml, 15.62μg/ml, 
7.81μg/ml, and 3.90μg/ml. 
This formula and process was used for Tetracycline, with a starting concentration of 500μg/ml, and 
Ampicillin, with a starting concentration of 1mg/ml, so that the final concentrations in the tubes 
were the same for each antibiotic or antimicrobial peptide. When 50μl of each antibiotic solution is 
added to 450μl, the solution becomes diluted in the suspension, lowering the working concentration 
of the antibiotic to one tenth that of the original concentration. 
So, the final working concentration of the antibiotic solutions was 25μg/ml, 12.5µg/ml, 6.25µg/ml, 
3.125µg/ml, 1.562µg/ml, 0.781µg/ml, and 0.390µg/ml. 
 
Adding Bacteria to Antibiotic Solutions: 
In this part of the procedure, 50μl of each antibiotic solution were pipetted into 7 sterile glass tubes, 
one for each concentration. Then, 450μl of the bacteria solution were added to each tube. This was 
done with each antibiotic with E.coli bacteria, and again with the S. aureus. These tubes were then 
covered with parafilm and incubated at 37ºC. 
 
 
Figure 34: Bacteria and antibiotics are mixed together. 
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Plating: 
The 500 times diluted bacteria suspension was diluted 500 times more. Then, 100µl of this 
suspension was pipeted onto each LB agar plate. A sterilized Drigalski spatula was then used to 
spread the suspension over the agar, until the plate began to dry. Then each plate was covered and 
incubated. Colonies were counted after 24 hours.  
Day Three 
Bacteria growth was observed after 24 hours in the antibiotic and bacterial suspensions. 
Colonies were counted on the agar plates after 24 hours. 
 
Figure 35: Colonies are counted to check consistency. 
Day Four 
Bacteria growth was observed after 48 hours in the antibiotic and bacteria suspensions.  
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Experimental Results 
 
Table 4: MIC results for the 1st week 
Week 1 E. coli S. aureus 
Tetracycline 125µg/ml 15,62µg/ml 
Ampicillin 250µg/ml 31,25µg/ml 
 
Table 5: MIC results for the 2nd week 
Week 2 E. coli S. aureus 
Tetracycline 62,5µg/ml 7,8µg/ml 
Ampicillin >125µg/ml No MIC* 
Polymyxin B 3,9µg/ml >125µg/ml 
*Measuring errors occurred. 
 
 
 
Figure 36: Clear difference between zero growth and bacterial growth, after MIC testing. 
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Discussion and conclusion 
 
The discovery of penicillin was a major breakthrough in modern medicine, and a great part of the 
scientific community believed that the end of the infectious diseases was near. However in 1960 the 
discovery of antibiotic resistance plasmids (Davies, 2010), proved that not only were bacteria 
capable of developing ways to avoid the action of antimicrobials, but they were able to share the 
genetic information that codifies resistance. 
The problem becomes bigger now at days; it is possible to find multidrug resistant strains that are 
not susceptible to almost any antibiotic. This is especially important due to the fact that bacteria are 
capable of adapting to their environment. Through the history of antibiotics it was believed that the 
acquisition of r genes was only possible under laboratory conditions. However, there are extensive 
studies that prove that HGT is possible and relatively easy in vivo, which should be a reminder that 
if resistance is biochemically possible, it will occur (Davies, 2010). 
Antimicrobials have been used extensively in many fields. For the last 10 years, the scientific 
community has been concerned over the fact that some microbes that were sensitive to specific 
antimicrobials have now developed mechanisms, which impedes the effect of the drug. 
As it has been extensively explained throughout this work and by many authors, the origins of 
antimicrobial resistance are still not completely clear, but the steps towards solving the problem are 
being taken. For example, the ban of antibiotics as growth promoters in the European Union helped 
reduce the incidence of resistance within the EU. But the problem remains; not only because of the 
use of antibiotics as growth promoters or as prophylactic measures in agriculture and aquaculture, 
but because there is a lack of information for the user, the medical personnel and society in general. 
Also there are questions that still have to be answered: why are the resistance levels in developing 
countries such as Brazil,  equal or lower that those seen in developed countries such as Canada. 
Why, after more than 60 years, does group A β- Streptococcus continue to be susceptible to 
penicillin but not always to erythromycin. And why are other members of the Streptococcus family, 
such as Streptococcus pneumonia, after decades of remaining susceptible to penicillin, now capable 
of presenting  high-level resistance to penicillin (Alanis, 2005). The answers to these questions may 
hold the key to understanding the mechanisms that lead to bacterial resistance, but also to 
developing new strategies in the creation of new antibiotics. 
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The problem of resistance has evolved by several means. Due to pathogenic bacteria’s ability to 
adapt rapidly, antibiotics should be used sparingly, and with caution. Despite this fact, antibiotics 
continue to be considered as “ordinary” drugs, and are prescribed by physicians with little concern 
of making a proper diagnosis. 
These doctors do not have many restrictions on the antibiotics that they prescribe, and therefore 
often do so when it is not necessary. For example, antibiotics are sometimes given to patients who 
are suffering from a common cold or other respiratory tract syndromes that are often caused by 
viruses. A viral infection cannot be cured with antibiotics, and therefore the antibiotics will only 
create a selective pressure on the bacteria naturally present in the body, increasing resistance. 
Furthermore, in some regions, particularly in developing countries, it is common practice to self-
medicate, as antibiotics in these places can often be bought over the counter. This leads to a steep 
increase in antibiotic resistance, as the consumers of antibiotics have no medical knowledge 
whatsoever and therefore cannot make an educated decision on whether or not antibiotic treatment 
is appropriate for the infection that they have.  
Based on the evidence of recent studies, resistance toward antimicrobials is constantly increasing in 
Escherichia coli and Staphylococcus aureus bacteria strains (Table 2). 
While this in itself is worrying, these are only two of the many species of bacteria that are causing a 
problem due to resistance. In addition to E. coli, MRSA, and other strains of S. aureus, bacteria 
including Enterococcus, Streptococcus pneumoniae and Salmonella are also currently causing a 
grave threat to human health (Danmap, 2004). As bacteria develop resistance to a particular 
antimicrobial, new ones must be developed to replace the ones that have become useless due to 
resistance. As bacteria are now developing resistance at an alarming rate, an increase in the amount 
of antimicrobials being developed is necessary in order to keep up with the rapid evolution of 
bacterial pathogens. Unfortunately, the opposite is occurring. Despite increasing demand, very few 
new drugs against microbes are being developed. This is detrimental, in light of the increasing 
mortality due to antibiotic resistant bacterial infections. 
New studies have shown that vaccinations might be an effective preventative measure against 
infections caused by S. aureus in the future (Spellberg, 2011). 
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Predominantly, however, new research must be done to develop new antibiotic drugs to fight the 
bacteria strains that are resistant to the antibiotics already on the market, as vaccinations only work 
on a small group of bacteria (Spellberg, 2011). Antimicrobial peptides, for instance, may provide 
an acceptable and efficient alternative to conventional antibiotics in the near future.  
Despite growing demand, the rate of antibiotic drug development is currently at a record low. This 
is due to several factors. First of all, the new antibiotic drugs must work in ways different than the 
drugs that are useless due to resistance. As more drugs are being developed, it becomes 
increasingly difficult to develop new antibiotics with unique mechanisms of action that have not 
been used previously. Furthermore, there is very little incentive for pharmaceutical companies to 
invest in the development of new antibiotics, as developing a new drug often takes up to 10 years 
and costs $800 million to produce. In addition to this, the new drug may only be affective for a 
short time before pathogenic bacteria develop resistance to it. Therefore, it is a very large and risky 
investment for companies to make, leading to a decrease in drug development.  
While several new antibacterial drugs have been made available against Gram-positive cocci 
recently, the situation is completely different when looking at Gram-negative bacteria. 
Unfortunately no new Gram-negative antibiotics are to be expected in the near future. This will 
likely cause an increase in mortality due to infections of Gram-negative bacteria such as multi drug 
resistant Escherichia coli. 
Antimicrobial peptides are the alternative to antibiotics because they have many beneficial 
properties that should be taken advantage of. Further research and development into the matter 
would expose many more options to fight microbes that are desperately needed, especially 
regarding Gram-negative bacteria. Eukaryotic AMP’s are broad spectrum, but slightly toxic, 
bacteriocins that are very specific, but not toxic. Phage-encoded AMP’s are very effective at 
bypassing the membrane and opening the cell wall with lytic activity (Parisien et al. 2007). 
Furthermore, when considering AMP’s as a whole they are fast acting, effective, and bacteria has a 
harder time developing resistance to them.  
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Not to mention, AMP’s have bonus effects like being able to speed up the healing of wounds, stop 
inflammation, and have immunomodualtory properties that help the host’s immune system fight off 
the infection. Development of AMP’s offers a wide variety because they are found in all living 
things, and can be synthesized to increase their antimicrobial activity by adding amino acids or 
changing the structure (Jenssen et al. 2006). The electrostatic and the amphipathic form allow it to 
penetrate and kill bacteria at low concentrations. 
The question which inspired the research and experiments of this report was whether or not 
antimicrobial peptides provided an efficient alternative to conventional antibiotics. Based on the 
results, it can be concluded that the antimicrobial peptide polymyxin B provides a decent 
alternative to Tetracyline and Ampicillin in the treatment of E. coli infections, as the MIC was 
125µg/ml for Tetracycline and 250µg/ml for Ampicillin, while the MIC was only 3.90µg/ml.  
The concentrations which are needed to inhibit E. coli bacterial growth are much lower for 
Polymyxin B, than for Ampicillin and Tetracycline. This proves that Polymyxin B is much more 
efficient in treating E. coli than the conventional antibiotics tested. For the treatment of S. aureus, it 
is necessary to test a polypeptide which is capable to target Gram-positive cocci, since Polymyxin 
B is specific to Gram-negative bacteria. However, from the positive results in the E. coli tests, it 
can be argued that Polymyxin B should definitely be developed as an alternative to conventional 
antibiotics, for the treatment of bacterial infections. 
Measures have been taken in recent years to slow down antibiotic resistance. For example, in the 
early 2000s in France, a program was launched, which led to a decrease in antibiotic consumption 
of 23%. This shows that by restricting the availability of antibiotics, or by educating the general 
public and medical professionals of the seriousness of this issue, the rate at which bacteria strains 
develop resistance to antimicrobial drugs can be reduced. 
Both the development of new drugs, and local and national programs to restrict antibiotic use must 
be encouraged, if we are to solve the growing problem of antibiotic resistant bacteria. 
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Appendix 
 
Amino acids 
Amino acids are the monomers that make up polypeptides.  
Structure:  
They are organic molecules, and are made up of two components: an amino group and a carboxyl 
group. An amino group consists of a nitrogen atom, which is bonded to two hydrogen atoms 
(Campbell, Reece 2011). An asymmetric carbon atom, the alpha carbon, in located at the center of 
the molecule. Attached to this carbon are the carboxyl group, the amino group, and a side chain, 
which is different for each of the 20 amino acids (Campbell, Reece 2011).  
Side Chains: 
The characteristics of an amino acid are determined by the physical and chemical properties of its 
side chain. For example, if the side chain is nonpolar, then the amino acid is hydrophobic. If the 
side chain is negative in charge, then the amino acid will be acidic (Campbell, Reece 2011).  
 
Figure 37: The formation of peptide bonds, by dehydration reactions. 
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Polypeptides 
 
A polypeptide is made up of many amino acids linked together by peptide bonds. 
Structure: 
There are several levels of polypeptide structure. The primary structure consists of a single chain of 
amino acids linked together by peptide bonds. The secondary structure of the polypeptide is formed 
by hydrogen bonds between the oxygen atoms of the carboxyl group and the hydrogen atoms of the 
amino group (Campbell, Reece 2011). This changes the shape of the polypeptide, creating twists or 
pleats. The tertiary structure is formed by interactions between the side chains of the amino acids. 
This can cause the peptide to fold in on itself, and take on a unique shape (Campbell, Reece 2011). 
 
Formation of polypeptides 
 
Two amino acids can become joined if the carboxyl group of one is adjacent to the amino group of 
the other. A covalent bond, called a peptide bond, forms between the two through a dehydration 
reaction (Campbell, Reece 2011). A polypeptide is formed when many amino acids are linked 
together by peptide bonds.  
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OD600 
 
The abbreviation OD stands for optical density. OD600 is a method used to measure the absorbance 
of wavelengths at 600nm. The more bacteria there are in a suspension, the more light will be 
absorbed. Bacteria are usually grown until they reach an OD600 of 0.4 (OD600 2011). At this point, 
the bacteria are still exhibiting exponential growth, and have not yet reached a growth limit. 
 
Figure 38: Rate of bacteria growth at 37ºC. 
 
Antimicrobial peptide sequence 
 
As directed from the page of reference (Hancock, Chapple, 2003), bold face letters depict 
positively charged amino acids, and letters inside parenthesis denote that they are cyclized. The 
subscript numbers represent amino acids that are joined by either cysteine disulfides or (for nisin) 
thioether bridges, and the d subscript denotes the d-enantiomer while all others denote the l-
enantiomer. The amino acid letter stand for: A= Alanine B= Diaminobutyrate C= Cysteine D= 
Aspartic Acid E= Glutamic Acid F= Phenylalanine G= Glycine H= Histidine I= Isoleucine K= 
Lysine L= Leucine M= Methionine N= Asparagine O= Ornithine P= Proline Q= Glutamine R= 
Arginine S= Serine T= Threonine U= 2,3-didehydroalanine V=Valine W=Tryptophan X= 2,3-
didehydrobutyrine Y= Tyrosine Z= -aminobutyrate. 
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Enantiomers 
 
Chiral molecules are molecules that have two types of structures that are mirror images, but not 
identical called enantiomers; to be specific, only the chemical arrangement is different. The unique 
characteristic is that the two structures direct plane-polarized light in opposite directions. If an 
amino acid has an “l” then it means it directs the light counter clockwise, or levorotation, and if it 
has a d it directs the light clockwise, or dextrorotation. Even though they are mirror images of each 
other they do cause different chemical reactions. Amino acids function depends on its shape. 
Additional pictures 
 
Figure 39: Bacteria are spread on the agar plate, for counting. 
 
 
Glossary 
 
 Amphipathic: Structure that contains both a hydrophilic domain and hydrophobic domain. 
 Enantiomer:  One of two stereoisomers that are mirror images of each other that are non-
superposable (not identical) 
 Endotoxins: Lipopolysaccharide on the outer membrane of bacteria, responsible for many 
virulent effects of Gram-negative bacteria. 
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 Enterotoxins: Group of toxins that act on intestinal mucosa. They disturb ion and water 
transport systems, thereby causing diarrhea.  
 Epidemic: An outbreak of a disease. 
 Fimbriae: Finger-like projections on a bacteria cell, which allow the cell to adhere to other 
cells. 
 Hydrophilic: water-soluble domain. 
 Hydrophobic: fat-soluble domain. 
 Immunomodualtor: A substance that alters the immune response by augmenting or 
reducing the ability of the immune system to produce antibodies or sensitized cells that 
recognize and react with the antigen that initiated their production 
 LB: Lysogeny broth, a nutritionally rich medium, is primarily used for         
the growth of bacteria. There are several common formulations of LB. Although they are 
different, they generally share a somewhat similar composition of ingredients used to 
promote growth, including the following: Peptides and casein peptones, 
vitamins (including B vitamins), trace elements (e.g. nitrogen, sulfur, magnesium) and 
minerals 
 Leukocyte: White blood cells that function in immune support, protecting the body against 
foreign microorganisms. 
 Lysis: Rupture; breaking down of cell that compromises it’s integrity. 
 Neutrophils: white blood cells found in mammals. 
 Nosocomial: Of or being a secondary disorder associated with being treated in a hospital 
but unrelated to the patient's primary condition 
 Osmolysis: Rupture due to osmotic pressure. 
 Pandemic: A global epidemic. 
 Phagocyte: A cell that engulfs and breaks down invading microorganisms in the body. 
 Zoonotic:  is an infectious disease that is transmitted between species (sometimes by 
a vector) from animals to humans or from humans to animals. 
 Zwitterionic: Molecules that discharge a neutral charge or both positive and negative 
charges. 
